Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $9.3 million.

  • Century Therapeutics' Gains from Investment Securities rose 7399.11% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year increase of 7399.11%. This contributed to the annual value of $5.3 million for FY2024, which is 3484.56% up from last year.
  • Latest data reveals that Century Therapeutics reported Gains from Investment Securities of $9.3 million as of Q3 2025, which was up 7399.11% from $6.8 million recorded in Q2 2025.
  • Century Therapeutics' Gains from Investment Securities' 5-year high stood at $10.4 million during Q1 2023, with a 5-year trough of $6000.0 in Q4 2024.
  • Its 4-year average for Gains from Investment Securities is $5.9 million, with a median of $6.7 million in 2025.
  • In the last 5 years, Century Therapeutics' Gains from Investment Securities crashed by 9943.45% in 2024 and then soared by 25627.29% in 2025.
  • Quarter analysis of 4 years shows Century Therapeutics' Gains from Investment Securities stood at $7.4 million in 2022, then tumbled by 85.71% to $1.1 million in 2023, then crashed by 99.43% to $6000.0 in 2024, then surged by 155272.38% to $9.3 million in 2025.
  • Its Gains from Investment Securities stands at $9.3 million for Q3 2025, versus $6.8 million for Q2 2025 and $6.6 million for Q1 2025.